Incidence of factor V Leiden in patients with acute myocardial infarction

Journal of Thrombosis and Thrombolysis

Volumn 9, Issue 1, 2000, Pages 43-45

  Gowda, Manohar S ^a   Zucker, Marjorie L ^a,b   Vacek, James L ^a   Carriger, William L ^a   Van Laeys, Dana L ^a   Rachel, Jane M ^a   Strope, Barbara D ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Department of Pathology ^*  (United States)

Author keywords

Activated protein C resistance; Factor V Leiden; Myocardial infarction; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD DONOR; BLOOD LEVEL; CONTROLLED STUDY; DNA DETERMINATION; ELECTROCARDIOGRAM; FEMALE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0033973557     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018652429633     Document Type: Article

References (17)

1. Dahlback B. Physiological anticoagulation: Resistance to activated protein C and venus thromboembolism. J Clin Invest 1994;94:923-927.
2. Dahlback B, Carlsson M, Svenson PJ. Familial thrombophilia due to previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-1008.
3. Nichols WL, Heit JA. Activated protein C resistance and thrombosis. Mayo Clin Proc 1996;71:897-898.
4. Kontula K, Ylikorkala A, Miettinen H. Arg506Gln factor V mutation (Factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995;73:558-560.
5. Bertina RM, Koeleman BPC, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
6. Dahlback B. Inherited thrombophilia: Resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995;85:607-614.
7. Dahlback, B. Resistance to activated protein C, Arg506Gln mutation in factor V gene, and venous thrombosis. Thromb Haemost 1995;73:739-742.
8. Holm J, Zoller B, Svensson PJ. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994;344:952-954.
9. Rosendal FR, Siscovick SM, Schwartz RK. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817-2821.
10. Sumani NJ, Lodwick D, Martin D, Kimber P. Evaluation of activated protein C and risk of premature myocardial infarction. Lancet 1994;344:1709-1711.
11. VanBockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nat Med 1995;1:185-186.
12. Ardissiono D, Peyvandi F, Merlini PA. Factor V (Arg506 -Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 1996;75:701-702.
13. Marz W, Seydewitz H, Winkelmann B. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995;345:526-527.
14. Ridker PM, Hennekens CH, Linpaintner K. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thromboembolism in apparently healthy men. N Engl J Med 1995;332:912-917.
15. Henkens CM A, Bom VJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C: Influence of oral contraceptives and sex. Thromb Haemost 1995;344"2-103.
16. Coughlin SR. Thrombin receptor structure and function. Thromb Haemost 1993;66:184-187.
17. Ridker PM, Miletich JP, Hennekens CH. Ethnic distribution of Factor V Leiden in 4047 men and women. JAMA 1997;277:1305-1307.